Oxygen therapy study aims to Fine-Tune care for ICU patients
NCT ID NCT05590130
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looks at how different oxygen level targets and two types of oximeters affect the amount of oxygen given to patients in the intensive care unit. Researchers will test four combinations of target (90% or 94% oxygen saturation) and oximeter (Philips or Nonin) in 40 adults after heart surgery. The goal is to see which setup uses less oxygen while keeping patients safe, potentially reducing oxygen toxicity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors choose better oxygen targets and oximeters to reduce oxygen waste and risk of oxygen toxicity.
- What could go wrong
- This is a small, early-stage study with only 40 participants, mostly light-skinned. Results may not apply to all patients or settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OXYGEN TOXICITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut Universitaire de Cardiologie et de Pneumologie de Québec
RECRUITINGQuébec, Quebec, G1V4G5, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Spinal zaps could reboot breathing after brain injury
- Spinal cord zap may help people breathe again after neck injury
- Tweaking ventilator settings could ease breathlessness and cut PTSD risk in ICU survivors
- AI could predict the perfect moment to take ICU patients off ventilators
- Could a watchful software save ICU patients from organ failure?
- New anxiety program for ICU survivors shows promise in early trial